,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2019', 'fs': 'Mar 2019', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004WndGUAS'}, 'Id': 'a0P2P000004WndGUAS', 'Event_Date__c': '2019-03-08', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Mar 2019', 'Status_History__c': 'a132P000000Ard7QAC'}, 'change': None}]",Mar 2019,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2019', 'fs': 'Dec 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004WndHUAS'}, 'Id': 'a0P2P000004WndHUAS', 'Event_Date__c': '2019-12-03', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2019', 'Status_History__c': 'a132P000000BTr9QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> access to lidocaine (lignocaine) gel 2%, urethral syringe be widened to include the treatment of intractable rectal pain/tenesmus with a low priority within the context of anaesthetic treatments. The Subcommittee made this recommendation based on the high unmet health need of patients with intractable rectal pain/tenesmus who may require hospice admission for pain relief, acknowledging that there is poor evidence to support lidocaine gel in this indication and that further evidence is unlikely to be generated.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that lidocaine (lignocaine) gel 2%, urethral syringe should be listed with the following Special Authority criteria:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE </b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Gel 2%, 10ml urethral syringe </b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Special Authority for Subsidy</b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application – (intractable rectal pain) </b><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 3 months. </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has intractable rectal pain/tenesmus, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used in palliative care, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Lidocaine gel 2%, 10ml urethral syringe is for rectal administration, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is for a maximum duration of 3 months.</span></p><p><br></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> access to lidocaine (lignocaine) gel 2%, urethral syringe be widened to include the treatment of intractable rectal pain/tenesmus with a low priority within the context of anaesthetic treatments. The Subcommittee made this recommendation based on the high unmet health need of patients with intractable rectal pain/tenesmus who may require hospice admission for pain relief, acknowledging that there is poor evidence to support lidocaine gel in this indication and that further evidence is unlikely to be generated.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that lidocaine (lignocaine) gel 2%, urethral syringe should be listed with the following Special Authority criteria:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE </b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Gel 2%, 10ml urethral syringe </b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Special Authority for Subsidy</b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application – (intractable rectal pain) </b><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 3 months. </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has intractable rectal pain/tenesmus, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used in palliative care, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Lidocaine gel 2%, 10ml urethral syringe is for rectal administration, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is for a maximum duration of 3 months.</span></p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lidocaine gel 2%, urethral syringe has been listed with sole supply status since 1 November 2019 and that this resulted in a reduced cost per syringe. The Subcommittee noted that in response to the price reduction, an application had been received from two palliative care practitioners to widen access to meet an unmet clinical need by including the use in rectal pain/tenesmus. The Subcommittee considered that the key question to be addressed was whether access to lidocaine gel 2%, urethral syringe should be widened to include rectal application in the community and hospital settings.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rectal tenesmus is the persistent, painful sensation of incomplete evacuation of the bowel that is experienced as distressing, episodic pain between one to six times a day. The Subcommittee noted that rectal pain/tenesmus is an infrequent condition which generally results from an underlying malignancy such as rectal carcinoma and that it can have a significant impact on a person’s quality of life. The Subcommittee noted that the overall prevalence of rectal tenesmus is unknown, however, the prevalence in people with recurrent rectal carcinoma is approximately 14%. The Subcommittee noted that some patients may not experience sufficient relief with conventional treatments, in which case their rectal pain/tenesmus is described as intractable.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that intractable rectal tenesmus is generally a late presenting symptom in the palliative care setting. The Subcommittee considered that in the majority of patients the maximum duration of treatment would be two months in the end of life setting. The Subcommittee considered that if the symptoms were unable to be controlled then the patient would instead be admitted to hospice for pain relief.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of the underlying malignancy may be an option for patients who are suitable for surgery, radiotherapy and/or; other treatments for rectal pain/tenesmus may include lumbar sympathectomy, endoscopic laser therapy or medicines. The Subcommittee noted that medicines such as amitriptyline, bupivacaine, diltiazem, gabapentin, lidocaine, methadone, mexiletine hydrochloride, nifedipine and other opioids may be used either alone or in a combination, with or without other interventions. The Subcommittee noted that some of these medicines are funded for unrestricted use in the community (Section B of the Pharmaceutical Schedule), enabling use in hospice, but that some patients will experience symptoms that are refractory to the funded treatment options. The Subcommittee noted that there is no topical anaesthetic funded for this use in the community setting.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that bupivacaine hydrochloride solution for injection is listed in Section H of the Pharmaceutical Schedule for hospital use with presentations ranging from 1.25 mg per ml to 5 mg per ml, but is not currently listed in Section B for community use and is not readily used or accessible in hospice settings. The Subcommittee considered that bupivacaine is long-acting and therefore may not be appropriate for episodic symptoms. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lidocaine (lignocaine) gel 2% is currently listed on Section B of the Pharmaceutical Schedule, available as a tube and as a urethral syringe (US); both presentations are funded only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly. </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that opioids are often ineffective in treating rectal pain/tenesmus and that their use is generally avoided if possible. The Subcommittee noted that local or topical anaesthetics have few systemic side effects but may provide benefit only in some people. Members considered that glyceryl trinitrate, which is funded for treatment of chronic anal fissures in the community (Section B) and is listed in for hospital use (Section H) without restriction, may provide benefit for some patients when used in combination with other medicines. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that patients with intractable rectal pain/tenesmus have an unmet health need due to limitations of the currently funded pharmaceuticals and considered that having another treatment option available to treat intractable rectal pain/tenesmus and therefore delay or prevent hospice care would be desirable. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that use of lidocaine gel 2%, urethral syringe in New Zealand has increased over recent years and considered this is unlikely to be due to an increase in catheterisations (see also part 7.20 of this record). The Subcommittee noted that there are anecdotal reports of it being used in New Zealand for other indications including localised neuropathic pain, malignant wound or ulcer pain, postherpetic neuralgia in elderly patients experiencing side effects from oral or systemic agents, and occasionally for severe migraine, applied nasally at Accident &amp; Emergency clinics. The Subcommittee considered that, while some use in other indications may be appropriate and beneficial in specific cases despite limited evidence (if any) for such use, this use would be outside of the current funding restrictions.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that there is limited evidence for treatment of rectal pain/tenesmus in palliative care in general and noted that the applicants have not provided any evidence in support of the use of rectal administration of lidocaine specifically. The Subcommittee considered that in the palliative care setting evidence is often limited to anecdotal case reports.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a systematic review of the literature for efficacy of interventions for the palliative treatment of rectal tenesmus in patients with cancer, which identified 9 case series investigating pharmacological (bupivacaine, diltiazem, lidocaine, methadone, mexiletine hydrochloride and nifedipine), anaesthetic and endoscopic laser interventions (<a href=""https://journals.sagepub.com/doi/pdf/10.1177/0269216317697897"" target=""_blank"">Laoire AN et al. Palliative Medicine 2017;31:975-81</a>). The authors noted that heterogeneity of the case series prevented meta-analysis and concluded that there is a significant gap in research of palliative care for rectal tenesmus.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a single patient case report in support of the rectal administration of bupivacaine hydrochloride solution 0.05% - 0.1%, in which the patient achieved significant pain relief within 10 to 15 minutes post dose, with a duration of analgesia for 4.5 to 11 hours, and without any reported systemic effects (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199793/pdf/ott-7-1541.pdf"" target=""_blank"" style=""color: windowtext;"">Zaporowska-Stachowiak I et al. OncoTargets Ther 2014;7:1541-50</a>). The authors concluded that bupivacaine administered rectally was a valuable option for palliative treatment of rectal pain/tenesmus due to cancer. The Subcommittee noted that bupivacaine solution is not currently listed in Section H at the concentrations investigated.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that there are anecdotal reports of topical lidocaine gel 2%, urethral syringe used in combination with morphine to provide a successful treatment with one syringe per episode, and expert opinion reports stating that lidocaine is sometimes a beneficial therapy.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the evidence base for palliative treatment of rectal pain/tenesmus is poor, noting that it is based on anecdotal reports, case reports, case series and expert opinion. The Subcommittee noted that evidence from palliative care settings is known to be limited and can be affected by variation between treating centres. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that lidocaine gel 2%, urethral syringe could be more appropriate for treatment of intractable episodic rectal pain/tenesmus than other treatments such as rectal administration of bupivacaine solution; noting that bupivacaine is longer acting, is not available for use in community or hospice settings, and is not funded at the investigated concentrations. </p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that successful use of lidocaine gel 2%, urethral syringe for patients with rectal pain could delay or prevent hospice admissions and provide savings, noting the relatively low cost per dose of lidocaine compared to the cost of hospice care for pain relief. </p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the applicants’ estimate that roughly 60 to 65 people would be suitable to receive lidocaine gel 2%, urethral syringe annually for intractable rectal pain was reasonable, noting the applicants proposed dosing up to three times daily for two to three months. The Subcommittee considered that the likely use would be one to two syringes per day, up to a maximum of six per day in some cases per patient. The Subcommittee considered that the use of lidocaine in this setting would likely be in combination with other treatment options.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that if the restriction by endorsement was widened to include rectal administration in the palliative care setting, then there would likely be use beyond intractable rectal tenesmus, for example in indications such as ulcer or wound pain. The Subcommittee considered that funding lidocaine gel 2%, urethral syringe with Special Authority criteria, rather than funding with a restriction by endorsement, would help to limit its use to the intended patient population. The Subcommittee considered some private use (purchased privately) would also be likely to continue. </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that, due to the noted absence of evidence for interventions in palliative care, and the anecdotal reports of usage\xa0of lidocaine gel 2% urethral syringe outside of the funded indications, it would be useful for the Analgesics Subcommittee to review a PHARMAC-prepared paper on topical analgesia in palliative care in future. The Subcommittee considered that PHARMAC may like to further investigate the increasing use of lidocaine gel 2%, urethral syringe in other indications such as use for malignant wounds or ulcers, including estimates of patient numbers.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lidocaine gel 2%, urethral syringe has been listed with sole supply status since 1 November 2019 and that this resulted in a reduced cost per syringe. The Subcommittee noted that in response to the price reduction, an application had been received from two palliative care practitioners to widen access to meet an unmet clinical need by including the use in rectal pain/tenesmus. The Subcommittee considered that the key question to be addressed was whether access to lidocaine gel 2%, urethral syringe should be widened to include rectal application in the community and hospital settings.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rectal tenesmus is the persistent, painful sensation of incomplete evacuation of the bowel that is experienced as distressing, episodic pain between one to six times a day. The Subcommittee noted that rectal pain/tenesmus is an infrequent condition which generally results from an underlying malignancy such as rectal carcinoma and that it can have a significant impact on a person’s quality of life. The Subcommittee noted that the overall prevalence of rectal tenesmus is unknown, however, the prevalence in people with recurrent rectal carcinoma is approximately 14%. The Subcommittee noted that some patients may not experience sufficient relief with conventional treatments, in which case their rectal pain/tenesmus is described as intractable.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that intractable rectal tenesmus is generally a late presenting symptom in the palliative care setting. The Subcommittee considered that in the majority of patients the maximum duration of treatment would be two months in the end of life setting. The Subcommittee considered that if the symptoms were unable to be controlled then the patient would instead be admitted to hospice for pain relief.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of the underlying malignancy may be an option for patients who are suitable for surgery, radiotherapy and/or; other treatments for rectal pain/tenesmus may include lumbar sympathectomy, endoscopic laser therapy or medicines. The Subcommittee noted that medicines such as amitriptyline, bupivacaine, diltiazem, gabapentin, lidocaine, methadone, mexiletine hydrochloride, nifedipine and other opioids may be used either alone or in a combination, with or without other interventions. The Subcommittee noted that some of these medicines are funded for unrestricted use in the community (Section B of the Pharmaceutical Schedule), enabling use in hospice, but that some patients will experience symptoms that are refractory to the funded treatment options. The Subcommittee noted that there is no topical anaesthetic funded for this use in the community setting.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that bupivacaine hydrochloride solution for injection is listed in Section H of the Pharmaceutical Schedule for hospital use with presentations ranging from 1.25 mg per ml to 5 mg per ml, but is not currently listed in Section B for community use and is not readily used or accessible in hospice settings. The Subcommittee considered that bupivacaine is long-acting and therefore may not be appropriate for episodic symptoms. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lidocaine (lignocaine) gel 2% is currently listed on Section B of the Pharmaceutical Schedule, available as a tube and as a urethral syringe (US); both presentations are funded only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly. </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that opioids are often ineffective in treating rectal pain/tenesmus and that their use is generally avoided if possible. The Subcommittee noted that local or topical anaesthetics have few systemic side effects but may provide benefit only in some people. Members considered that glyceryl trinitrate, which is funded for treatment of chronic anal fissures in the community (Section B) and is listed in for hospital use (Section H) without restriction, may provide benefit for some patients when used in combination with other medicines. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that patients with intractable rectal pain/tenesmus have an unmet health need due to limitations of the currently funded pharmaceuticals and considered that having another treatment option available to treat intractable rectal pain/tenesmus and therefore delay or prevent hospice care would be desirable. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that use of lidocaine gel 2%, urethral syringe in New Zealand has increased over recent years and considered this is unlikely to be due to an increase in catheterisations (see also part 7.20 of this record). The Subcommittee noted that there are anecdotal reports of it being used in New Zealand for other indications including localised neuropathic pain, malignant wound or ulcer pain, postherpetic neuralgia in elderly patients experiencing side effects from oral or systemic agents, and occasionally for severe migraine, applied nasally at Accident &amp; Emergency clinics. The Subcommittee considered that, while some use in other indications may be appropriate and beneficial in specific cases despite limited evidence (if any) for such use, this use would be outside of the current funding restrictions.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that there is limited evidence for treatment of rectal pain/tenesmus in palliative care in general and noted that the applicants have not provided any evidence in support of the use of rectal administration of lidocaine specifically. The Subcommittee considered that in the palliative care setting evidence is often limited to anecdotal case reports.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a systematic review of the literature for efficacy of interventions for the palliative treatment of rectal tenesmus in patients with cancer, which identified 9 case series investigating pharmacological (bupivacaine, diltiazem, lidocaine, methadone, mexiletine hydrochloride and nifedipine), anaesthetic and endoscopic laser interventions (<a href=""https://journals.sagepub.com/doi/pdf/10.1177/0269216317697897"" target=""_blank"">Laoire AN et al. Palliative Medicine 2017;31:975-81</a>). The authors noted that heterogeneity of the case series prevented meta-analysis and concluded that there is a significant gap in research of palliative care for rectal tenesmus.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a single patient case report in support of the rectal administration of bupivacaine hydrochloride solution 0.05% - 0.1%, in which the patient achieved significant pain relief within 10 to 15 minutes post dose, with a duration of analgesia for 4.5 to 11 hours, and without any reported systemic effects (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199793/pdf/ott-7-1541.pdf"" target=""_blank"" style=""color: windowtext;"">Zaporowska-Stachowiak I et al. OncoTargets Ther 2014;7:1541-50</a>). The authors concluded that bupivacaine administered rectally was a valuable option for palliative treatment of rectal pain/tenesmus due to cancer. The Subcommittee noted that bupivacaine solution is not currently listed in Section H at the concentrations investigated.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that there are anecdotal reports of topical lidocaine gel 2%, urethral syringe used in combination with morphine to provide a successful treatment with one syringe per episode, and expert opinion reports stating that lidocaine is sometimes a beneficial therapy.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the evidence base for palliative treatment of rectal pain/tenesmus is poor, noting that it is based on anecdotal reports, case reports, case series and expert opinion. The Subcommittee noted that evidence from palliative care settings is known to be limited and can be affected by variation between treating centres. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that lidocaine gel 2%, urethral syringe could be more appropriate for treatment of intractable episodic rectal pain/tenesmus than other treatments such as rectal administration of bupivacaine solution; noting that bupivacaine is longer acting, is not available for use in community or hospice settings, and is not funded at the investigated concentrations. </p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that successful use of lidocaine gel 2%, urethral syringe for patients with rectal pain could delay or prevent hospice admissions and provide savings, noting the relatively low cost per dose of lidocaine compared to the cost of hospice care for pain relief. </p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the applicants’ estimate that roughly 60 to 65 people would be suitable to receive lidocaine gel 2%, urethral syringe annually for intractable rectal pain was reasonable, noting the applicants proposed dosing up to three times daily for two to three months. The Subcommittee considered that the likely use would be one to two syringes per day, up to a maximum of six per day in some cases per patient. The Subcommittee considered that the use of lidocaine in this setting would likely be in combination with other treatment options.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that if the restriction by endorsement was widened to include rectal administration in the palliative care setting, then there would likely be use beyond intractable rectal tenesmus, for example in indications such as ulcer or wound pain. The Subcommittee considered that funding lidocaine gel 2%, urethral syringe with Special Authority criteria, rather than funding with a restriction by endorsement, would help to limit its use to the intended patient population. The Subcommittee considered some private use (purchased privately) would also be likely to continue. </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that, due to the noted absence of evidence for interventions in palliative care, and the anecdotal reports of usage\xa0of lidocaine gel 2% urethral syringe outside of the funded indications, it would be useful for the Analgesics Subcommittee to review a PHARMAC-prepared paper on topical analgesia in palliative care in future. The Subcommittee considered that PHARMAC may like to further investigate the increasing use of lidocaine gel 2%, urethral syringe in other indications such as use for malignant wounds or ulcers, including estimates of patient numbers.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a clinician application requesting funded access of lidocaine (lignocaine) gel 2%, urethral syringe be widened to include the treatment of intractable rectal pain/tenesmus.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a clinician application requesting funded access of lidocaine (lignocaine) gel 2%, urethral syringe be widened to include the treatment of intractable rectal pain/tenesmus.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Regarding the application for lidocaine (lignocaine) gel 2 % urethral syringe for intractable rectal pain/tenesmus, the Committee noted the Subcommittee’s recommendation (paragraph 4.3), and considered that there is a high unmet health need for people with these symptoms in the end of life setting. The Committee considered that should lidocaine gel be funded for rectal administration there was a high risk of use in people with other indications, for example pruritis ani. The Committee considered that lidocaine gel is associated with a risk of contact dermatitis. The Committee considered it would therefore be appropriate to limit the use of rectal administration of this pharmaceutical to patients in the end of life setting, and that Special Authority criteria would be appropriate in this context.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Regarding the application for lidocaine (lignocaine) gel 2 % urethral syringe for intractable rectal pain/tenesmus, the Committee noted the Subcommittee’s recommendation (paragraph 4.3), and considered that there is a high unmet health need for people with these symptoms in the end of life setting. The Committee considered that should lidocaine gel be funded for rectal administration there was a high risk of use in people with other indications, for example pruritis ani. The Committee considered that lidocaine gel is associated with a risk of contact dermatitis. The Committee considered it would therefore be appropriate to limit the use of rectal administration of this pharmaceutical to patients in the end of life setting, and that Special Authority criteria would be appropriate in this context.</p>', 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2020', 'fs': 'Mar 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Analgesic Subcommittee at meeting Tuesday 3 December 2019.', 'fs': 'Clinical advice received from Analgesic Subcommittee at meeting Tuesday 3 December 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004WndIUAS'}, 'Id': 'a0P2P000004WndIUAS', 'Event_Date__c': '2020-03-03', 'Event_Description__c': 'Clinical advice received from Analgesic Subcommittee at meeting Tuesday 3 December 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Mar 2020', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> access to lidocaine (lignocaine) gel 2%, urethral syringe be widened to include the treatment of intractable rectal pain/tenesmus with a low priority within the context of anaesthetic treatments. The Subcommittee made this recommendation based on the high unmet health need of patients with intractable rectal pain/tenesmus who may require hospice admission for pain relief, acknowledging that there is poor evidence to support lidocaine gel in this indication and that further evidence is unlikely to be generated.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that lidocaine (lignocaine) gel 2%, urethral syringe should be listed with the following Special Authority criteria:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE </b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Gel 2%, 10ml urethral syringe </b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Special Authority for Subsidy</b></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application – (intractable rectal pain) </b><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 3 months. </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has intractable rectal pain/tenesmus, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used in palliative care, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Lidocaine gel 2%, 10ml urethral syringe is for rectal administration, and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is for a maximum duration of 3 months.</span></p><p><br></p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a clinician application requesting funded access of lidocaine (lignocaine) gel 2%, urethral syringe be widened to include the treatment of intractable rectal pain/tenesmus.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lidocaine gel 2%, urethral syringe has been listed with sole supply status since 1 November 2019 and that this resulted in a reduced cost per syringe. The Subcommittee noted that in response to the price reduction, an application had been received from two palliative care practitioners to widen access to meet an unmet clinical need by including the use in rectal pain/tenesmus. The Subcommittee considered that the key question to be addressed was whether access to lidocaine gel 2%, urethral syringe should be widened to include rectal application in the community and hospital settings.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rectal tenesmus is the persistent, painful sensation of incomplete evacuation of the bowel that is experienced as distressing, episodic pain between one to six times a day. The Subcommittee noted that rectal pain/tenesmus is an infrequent condition which generally results from an underlying malignancy such as rectal carcinoma and that it can have a significant impact on a person’s quality of life. The Subcommittee noted that the overall prevalence of rectal tenesmus is unknown, however, the prevalence in people with recurrent rectal carcinoma is approximately 14%. The Subcommittee noted that some patients may not experience sufficient relief with conventional treatments, in which case their rectal pain/tenesmus is described as intractable.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that intractable rectal tenesmus is generally a late presenting symptom in the palliative care setting. The Subcommittee considered that in the majority of patients the maximum duration of treatment would be two months in the end of life setting. The Subcommittee considered that if the symptoms were unable to be controlled then the patient would instead be admitted to hospice for pain relief.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of the underlying malignancy may be an option for patients who are suitable for surgery, radiotherapy and/or; other treatments for rectal pain/tenesmus may include lumbar sympathectomy, endoscopic laser therapy or medicines. The Subcommittee noted that medicines such as amitriptyline, bupivacaine, diltiazem, gabapentin, lidocaine, methadone, mexiletine hydrochloride, nifedipine and other opioids may be used either alone or in a combination, with or without other interventions. The Subcommittee noted that some of these medicines are funded for unrestricted use in the community (Section B of the Pharmaceutical Schedule), enabling use in hospice, but that some patients will experience symptoms that are refractory to the funded treatment options. The Subcommittee noted that there is no topical anaesthetic funded for this use in the community setting.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that bupivacaine hydrochloride solution for injection is listed in Section H of the Pharmaceutical Schedule for hospital use with presentations ranging from 1.25 mg per ml to 5 mg per ml, but is not currently listed in Section B for community use and is not readily used or accessible in hospice settings. The Subcommittee considered that bupivacaine is long-acting and therefore may not be appropriate for episodic symptoms. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lidocaine (lignocaine) gel 2% is currently listed on Section B of the Pharmaceutical Schedule, available as a tube and as a urethral syringe (US); both presentations are funded only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly. </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that opioids are often ineffective in treating rectal pain/tenesmus and that their use is generally avoided if possible. The Subcommittee noted that local or topical anaesthetics have few systemic side effects but may provide benefit only in some people. Members considered that glyceryl trinitrate, which is funded for treatment of chronic anal fissures in the community (Section B) and is listed in for hospital use (Section H) without restriction, may provide benefit for some patients when used in combination with other medicines. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that patients with intractable rectal pain/tenesmus have an unmet health need due to limitations of the currently funded pharmaceuticals and considered that having another treatment option available to treat intractable rectal pain/tenesmus and therefore delay or prevent hospice care would be desirable. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that use of lidocaine gel 2%, urethral syringe in New Zealand has increased over recent years and considered this is unlikely to be due to an increase in catheterisations (see also part 7.20 of this record). The Subcommittee noted that there are anecdotal reports of it being used in New Zealand for other indications including localised neuropathic pain, malignant wound or ulcer pain, postherpetic neuralgia in elderly patients experiencing side effects from oral or systemic agents, and occasionally for severe migraine, applied nasally at Accident &amp; Emergency clinics. The Subcommittee considered that, while some use in other indications may be appropriate and beneficial in specific cases despite limited evidence (if any) for such use, this use would be outside of the current funding restrictions.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted that there is limited evidence for treatment of rectal pain/tenesmus in palliative care in general and noted that the applicants have not provided any evidence in support of the use of rectal administration of lidocaine specifically. The Subcommittee considered that in the palliative care setting evidence is often limited to anecdotal case reports.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a systematic review of the literature for efficacy of interventions for the palliative treatment of rectal tenesmus in patients with cancer, which identified 9 case series investigating pharmacological (bupivacaine, diltiazem, lidocaine, methadone, mexiletine hydrochloride and nifedipine), anaesthetic and endoscopic laser interventions (<a href=""https://journals.sagepub.com/doi/pdf/10.1177/0269216317697897"" target=""_blank"">Laoire AN et al. Palliative Medicine 2017;31:975-81</a>). The authors noted that heterogeneity of the case series prevented meta-analysis and concluded that there is a significant gap in research of palliative care for rectal tenesmus.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a single patient case report in support of the rectal administration of bupivacaine hydrochloride solution 0.05% - 0.1%, in which the patient achieved significant pain relief within 10 to 15 minutes post dose, with a duration of analgesia for 4.5 to 11 hours, and without any reported systemic effects (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199793/pdf/ott-7-1541.pdf"" target=""_blank"" style=""color: windowtext;"">Zaporowska-Stachowiak I et al. OncoTargets Ther 2014;7:1541-50</a>). The authors concluded that bupivacaine administered rectally was a valuable option for palliative treatment of rectal pain/tenesmus due to cancer. The Subcommittee noted that bupivacaine solution is not currently listed in Section H at the concentrations investigated.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that there are anecdotal reports of topical lidocaine gel 2%, urethral syringe used in combination with morphine to provide a successful treatment with one syringe per episode, and expert opinion reports stating that lidocaine is sometimes a beneficial therapy.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the evidence base for palliative treatment of rectal pain/tenesmus is poor, noting that it is based on anecdotal reports, case reports, case series and expert opinion. The Subcommittee noted that evidence from palliative care settings is known to be limited and can be affected by variation between treating centres. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that lidocaine gel 2%, urethral syringe could be more appropriate for treatment of intractable episodic rectal pain/tenesmus than other treatments such as rectal administration of bupivacaine solution; noting that bupivacaine is longer acting, is not available for use in community or hospice settings, and is not funded at the investigated concentrations. </p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that successful use of lidocaine gel 2%, urethral syringe for patients with rectal pain could delay or prevent hospice admissions and provide savings, noting the relatively low cost per dose of lidocaine compared to the cost of hospice care for pain relief. </p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that the applicants’ estimate that roughly 60 to 65 people would be suitable to receive lidocaine gel 2%, urethral syringe annually for intractable rectal pain was reasonable, noting the applicants proposed dosing up to three times daily for two to three months. The Subcommittee considered that the likely use would be one to two syringes per day, up to a maximum of six per day in some cases per patient. The Subcommittee considered that the use of lidocaine in this setting would likely be in combination with other treatment options.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that if the restriction by endorsement was widened to include rectal administration in the palliative care setting, then there would likely be use beyond intractable rectal tenesmus, for example in indications such as ulcer or wound pain. The Subcommittee considered that funding lidocaine gel 2%, urethral syringe with Special Authority criteria, rather than funding with a restriction by endorsement, would help to limit its use to the intended patient population. The Subcommittee considered some private use (purchased privately) would also be likely to continue. </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that, due to the noted absence of evidence for interventions in palliative care, and the anecdotal reports of usage\xa0of lidocaine gel 2% urethral syringe outside of the funded indications, it would be useful for the Analgesics Subcommittee to review a PHARMAC-prepared paper on topical analgesia in palliative care in future. The Subcommittee considered that PHARMAC may like to further investigate the increasing use of lidocaine gel 2%, urethral syringe in other indications such as use for malignant wounds or ulcers, including estimates of patient numbers.\xa0</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Regarding the application for lidocaine (lignocaine) gel 2 % urethral syringe for intractable rectal pain/tenesmus, the Committee noted the Subcommittee’s recommendation (paragraph 4.3), and considered that there is a high unmet health need for people with these symptoms in the end of life setting. The Committee considered that should lidocaine gel be funded for rectal administration there was a high risk of use in people with other indications, for example pruritis ani. The Committee considered that lidocaine gel is associated with a risk of contact dermatitis. The Committee considered it would therefore be appropriate to limit the use of rectal administration of this pharmaceutical to patients in the end of life setting, and that Special Authority criteria would be appropriate in this context.</p>', 'Status_History__c': 'a132P000000BWijQAG'}, 'change': None}]",Dec 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004WndJUAS'}, 'Id': 'a0P2P000004WndJUAS', 'Event_Date__c': '2020-05-15', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BlHvQAK'}, 'change': None}]",May 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'Funded effective 1 September 2020', 'fs': 'Funded effective 1 September 2020', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004WndKUAS'}, 'Id': 'a0P2P000004WndKUAS', 'Event_Date__c': '2020-08-31', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'Funded effective 1 September 2020', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000CSO9QAO'}, 'change': None}]",Aug 2020,False,True
